Precision Life

PrecisionLife is an AI-driven precision medicine company focused on solving the world's most complex and costly chronic diseases. Using a world-leading Combinatorial Analytics and AI platform, PrecisionLife uncovers the biological drivers of disease that are invisible to other analytical approaches — including traditional methods such as GWAS, polygenic risk scores, generative AI, and panel-based diagnostics. The company serves biopharma organizations, healthcare systems, and research partners, with a mission to predict, treat, and prevent complex chronic diseases through precision medicine that works for everyone.

PrecisionLife has already made progress across more than 60 diseases spanning neuroscience, women's health, immunology, and beyond — building what it describes as the world's largest databank of novel chronic disease insights. Its research creates precision medicine opportunities for conditions affecting more than 5.4 billion people, while its proprietary repository encompasses over 100,000 protectable IP assets including biomarkers, risk models, and novel therapeutic targets.

Core Platform and Scientific Approach

• Combinatorial Analytics and AI platform that generates 10–100x the signal from just 10% of the data compared to conventional models
• Identifies causal disease biology and mechanistic patient subgroups that are invisible to other analytical approaches
• Stratifies complex chronic disease biology at unprecedented resolution, enabling a fundamentally mechanistic view of illness in individual patients
• Goes beyond symptom-based labels to determine the underlying biological drivers of disease, including factors that protect people from developing disease
• Analyzes multimodal and multiomic patient data through partnerships with biobanks, disease charities, research consortia, and global healthcare systems

Mechanostics® — Diagnostic and Prognostic Tools

• Mechanostics® represent a new generation of diagnostic and prognostic tools designed to accurately identify the cause of disease and personalize interventions earlier than previously possible
• Enable prediction of lifetime disease risk, treatment of underlying causes, and prevention of disease onset and progression
• Designed to be low-cost and non-invasive, supporting earlier and more accurate disease prediction and diagnosis
• Help clinicians match patients with the most effective treatments based on their personal biology
• Aim to improve health outcomes, increase healthspan, and reduce unsustainable costs to health systems

Drug Development and Clinical Trial Support

• Maximizes the probability of success in drug development by making precision approaches possible in complex chronic diseases
• Mechanistic insights and stratification biomarkers enrich clinical trials and reveal relationships between disease mechanisms, targets, treatments, and patients
• Supports pharmaceutical companies in developing better therapies and running more successful clinical trials
• Enables matching of the right patients to the right trials and treatments based on underlying biology
• Accelerates and de-risks clinical development by discovering novel and protective therapeutic targets

Key Capabilities and Differentiators

• Unique access to multimodal patient data across chronic diseases through an extensive network of biobank, charity, consortia, and healthcare system partnerships
• Ability to identify patient subgroups and causal biology that remain invisible to all other AI or data models
• Delivers actionable insights including mechanistic patient stratification, biomarker discovery, and identification of risk and resilience factors
• Brings precision to every stage of the biopharma and healthcare value chain — from target discovery through to clinical pathways
• Extends precision medicine beyond oncology to the broader landscape of prevalent and expensive chronic conditions

Notable Achievements and Recognition

• Identified the first genetic biomarkers to quantitatively predict GLP-1 efficacy response, in collaboration with Ovation
• Conducted the most detailed genetic analysis of myalgic encephalomyelitis ever performed
• Won Best Tech Innovation to Promote Health at the Tech Impact Awards
• Created precision medicine opportunities for diseases collectively affecting more than 5.4 billion people
• Built a proprietary repository of more than 100,000 protectable IP assets across chronic disease biology

Led by CEO Dr. Steve Gardner, a recognized global leader in precision medicine and human genetics, PrecisionLife is actively seeking partners across healthcare and biopharma to accelerate the delivery of better health outcomes for patients worldwide.